NASDAQ · JBIO
Jade Biosciences, Inc.
$14.02-$0.22 (-1.52%)
Jade Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.92% below the high.
Loading market information…
NASDAQ · IGMS · USD
Stock price, earnings
Quote as of Aug 14, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
IGM Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.36% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow IGM Biosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
IGM Biosciences, Inc. operates as a biotechnology firm dedicated to advancing Immunoglobulin M (IgM) antibodies. These novel therapeutic agents are being developed for a broad spectrum of conditions, including various cancers, infectious ailments, and autoimmune and inflammatory disorders. The company's most advanced experimental treatment is IGM-2323, a bispecific IgM antibody. This candidate is currently in Phase 2 clinical trials, evaluating its efficacy for patients diagnosed with relapsed or refractory B cell Non-Hodgkin's lymphoma (NHL). In addition to its lead program, IGM Biosciences maintains an active pipeline of other IgM antibodies. IGM-8444, an IgM antibody, is presently undergoing Phase 1 clinical trials for solid cancers. Another therapy in development, IGM-7354, is an anti-PD-L1 IgM antibody targeting both solid and hematologic malignancies. The company is also progressing IGM-2644, a bispecific T cell engaging IgM antibody designed to target CD38 and CD3 proteins, intended for individuals with multiple myeloma. Furthermore, IGM-2537, another bispecific T cell engaging IgM antibody, aims to target CD123 and CD3 proteins for potential use in acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences has a strategic collaboration and licensing arrangement with Genzyme Corporation. This partnership encompasses the generation, development, manufacturing, and commercialization of IgM antibodies. The company, initially founded in 1993 as Palingen, Inc., changed its name to IGM Biosciences, Inc. in 2010. Its corporate headquarters are located in Mountain View, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:33 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $497.00K-34.61% vs estimate |
| Q4 2023 | Mar 7, 2024 | -$1.01+4.72% vs estimate | $651.00K-6.93% vs estimate |
|---|
| Q3 2023 | Nov 13, 2023 | -$1.04+16.8% vs estimate | $509.00K-27.29% vs estimate |
|---|
THE ANALYST VIEW
18 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$14.02-$0.22 (-1.52%)
Jade Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.92% below the high.
$3.01-$0.17 (-5.35%)
Insight Molecular Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.63% below the high.
$1.20-$0.08 (-5.88%)
Berkeley Lights, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.78% below the high.
$22.93+$0.13 (+0.57%)
Landos Biopharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.04% below the high.
$1.07-$0.01 (-0.93%)
Surface Oncology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.17% below the high.
$2.38+$0.01 (+0.42%)
Heat Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 4.03% below the high.
$18.20+$16.47 (+952.02%)
Reneo Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.05% below the high.
$1.48+$0.01 (+0.68%)
Achilles Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 1.99% below the high.
